Subcostal Temporary Extravascular Pacing IV (STEP IV) Study

AtaCor Medical

Status: Completed

Conditions: Conduction Defect

Treatments: Device: AtaCor StealthTrac Lead

Study type: Interventional

Funder types: Industry

Identifiers

NCT05457673

DOC-10200

Details and patient eligibility

About

The STEP IV Study is a prospective, single-center, non-randomized, single-arm study without concurrent or historical controls. The objective of the study is to generate safety and performance data of the latest AtaCor EV Temporary Pacing Lead System to support the development of a future pivotal study with an indication limited to a maximum of 7 days.

Full description

The primary safety objective is freedom from Adverse Device Effects (ADE). The primary performance objective is summary statistics for pacing capture threshold, impedance, and sensed R-wave amplitude with the StealthTrac Lead from insertion through removal.

One (1) Investigational Site in Paraguay will participate with up to 16 subjects enrolled in the study. Subjects indicated for a closed-chest cardiac invasive procedure will be eligible for participation. Subjects undergoing a qualifying index procedure will have a Model AC-1013 StealthTrac Lead inserted and evaluated over the follow-up period (up to 7 days post procedure). Study participation requires 2 to 7 days with the Study Lead inserted. Following Study Lead removal, a final follow-up will be performed 27-33 days after lead insertion to assess for any latent Adverse Events. Subjects remain enrolled until completion of the 30-Day Follow Up.

The maximum duration for study participation is 33 days. The Study is expected to last up to 3 months after first enrollment: Enrollment and follow-up (1 month) and final report (2 months).

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. At least 18 years old
2. Indicated for closed-chest cardiac invasive procedure (e.g., transcatheter valve replacement, balloon valvuloplasty, permanent pacemaker implantation and pacing lead extractions/revisions)

Exclusion criteria

1. BMI ≥ 35 kg/m2

2. Septic shock

3. Severe anemia

4. Acute coronary syndrome within past 90 days

5. NYHA IV Functional Classification of heart failure within past 90 days

6. Circumstances that prevent data collection or follow-up (e.g., inability to perform a short walk with the Holter monitor)

7. Participation in any concurrent clinical study without prior written approval from the Sponsor

8. Inability or unwillingness to provide informed consent to participate in the Study

   Known prior history for any of the following:

9. Median or partial sternotomy

10. Surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium

11. Significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)

12. Thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical treatments/conditions which may complicate the AtaCor EV Temporary Pacing Lead System insertion procedure

13. Pericardial disease, pericarditis and mediastinitis

14. Medical treatments, surgeries or conditions that increase the potential for pericardial adhesions

15. FEV1 < 1 liter

16. Surgically corrected congenital heart disease (not including catheter-based procedures)

17. Allergies to the device materials such as stainless steel, titanium, platinum, iridium, polyethylene, polyurethane, polycarbonate, and silicone

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

AtaCor EV Temporary Pacing Lead System

Experimental group

Description:

Subjects implanted with the AtaCor StealthTrac Lead Model AC-1013

Treatment:

Device: AtaCor StealthTrac Lead